In this proof-of-concept study, we present a next-generation poxvirus vaccine that features a ‘two-in-one’ immunogen. Our protein vaccine construct, DAM, combines the monkeypox virus antigens A35 and M1, and was produced on the basis of structure-guided design. The DAM subunit vaccine elicited superior antiviral immunity with safety compared to cocktail vaccines or a live vaccinia virus vaccine.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLOS Negl. Trop. Dis. 16, e0010141 (2022). A review article on the changing epidemiology of human monkeypox.
McNeil, M. M. et al. Ischemic cardiac events and other adverse events following ACAM2000® smallpox vaccine in the Vaccine Adverse Event Reporting System. Vaccine 32, 4758–4765 (2014). This article reports adverse events following smallpox vaccine vaccination.
Heraud, J. M. et al. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177, 2552–2564 (2006). This article explores potential immunogens for co-immunization-based vaccines against infections with MPXV and smallpox.
Fang, Z. et al. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res. 33, 407–410 (2023). This article reports an issue of unbalanced bioavailability and immunogenicity for each component elicited by co-immunization-based vaccination strategy.
Fogg, C. N. et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25, 2787–2799 (2007). This article demonstrates that co-immunization with L1 and A33 effectively protects mice from lethal outcomes.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Wang, H. et al. Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against monkeypox virus. Nat. Immunol. https://doi.org/10.1038/s41590-023-01715-7 (2024).
Rights and permissions
About this article
Cite this article
Building a next-generation, two-component protein subunit vaccine against monkeypox virus. Nat Immunol 25, 200–201 (2024). https://doi.org/10.1038/s41590-023-01735-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-023-01735-3
